CD Diagnostics Acquires CLIA-Accredited Citrano Medical Laboratories
By LabMedica International staff writers Posted on 30 Oct 2012 |
CD Diagnostics, Inc. (Wynnewood, PA, USA) completed the purchase of 80% of the outstanding capital stock of Citrano Medical Laboratories, Inc. (CML; Towson, MD, USA).
CML provides clinical laboratory testing to physicians, clinics, and long-term care facilities. The combination of Citrano with CD Diagnostics creates an entity with both a strong R and D team that can produce Laboratory Developed Tests (LDTs), and a Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostics laboratory dedicated to customer service in which these tests can be run.
CD Diagnostics' immunoassays use a small sample of a patient’s joint fluid (synovial fluid) to measure the presence of proteins or biomarkers that are produced by the body and are specific to a particular joint disease. The presence of these biomarkers in elevated levels indicates that the patient is reacting to a specific joint disease and serves as a positive diagnosis. Results are accurate and available within five to ten minutes. The first test, an immunoassay to diagnose infection in joint replacements, is planned for release in November 2012. Joint infection is a very serious condition that must be ruled out with any joint disease.
The first test, CD Diagnostics’ new synovial fluid assays will enhance Citrano’s portfolio of testing services, which currently include hematology, urinalysis, and a broad range of other services.
The acquisition of Citrano is one of the milestones achieved by CD Diagnostics since its incorporation in December 2011. In June 2012, the company signed a commercialization agreement with an orthopedic company for the development of its infection test, receiving USD 2.9 million in milestone payments.
Richard Birkmeyer, CEO of CD Diagnostics, commented, “When you have inflammation in a joint, it can be a wide range of causes such as Lyme disease, gout, bacterial infection. Our test tells exactly what is causing that pain, no matter what the joint.” Tests for other joint diseases are in development.
Related Links:
CD Diagnostics, Inc.
Citrano Medical Laboratories, Inc.
CML provides clinical laboratory testing to physicians, clinics, and long-term care facilities. The combination of Citrano with CD Diagnostics creates an entity with both a strong R and D team that can produce Laboratory Developed Tests (LDTs), and a Clinical Laboratory Improvement Amendments (CLIA)-certified diagnostics laboratory dedicated to customer service in which these tests can be run.
CD Diagnostics' immunoassays use a small sample of a patient’s joint fluid (synovial fluid) to measure the presence of proteins or biomarkers that are produced by the body and are specific to a particular joint disease. The presence of these biomarkers in elevated levels indicates that the patient is reacting to a specific joint disease and serves as a positive diagnosis. Results are accurate and available within five to ten minutes. The first test, an immunoassay to diagnose infection in joint replacements, is planned for release in November 2012. Joint infection is a very serious condition that must be ruled out with any joint disease.
The first test, CD Diagnostics’ new synovial fluid assays will enhance Citrano’s portfolio of testing services, which currently include hematology, urinalysis, and a broad range of other services.
The acquisition of Citrano is one of the milestones achieved by CD Diagnostics since its incorporation in December 2011. In June 2012, the company signed a commercialization agreement with an orthopedic company for the development of its infection test, receiving USD 2.9 million in milestone payments.
Richard Birkmeyer, CEO of CD Diagnostics, commented, “When you have inflammation in a joint, it can be a wide range of causes such as Lyme disease, gout, bacterial infection. Our test tells exactly what is causing that pain, no matter what the joint.” Tests for other joint diseases are in development.
Related Links:
CD Diagnostics, Inc.
Citrano Medical Laboratories, Inc.
Latest Industry News
- Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
- Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
- New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
- Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
- Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration
- Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows
- Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’
- Research Collaboration to Advance AI-Enhanced, Real-Time Optical Imaging in Lung Cancer Biopsy
- CACLP 2025 Unites Global Innovators in IVD Industry
- Bio-Rad to Acquire Digital PCR Developer Stilla Technologies
- ABL Signs Know-How License and Transfer Agreement for Siemens’ Fast Track Diagnostics PCR Portfolio
- Becton Dickinson to Spin Out Biosciences and Diagnostic Solutions Business
- New Partnership Revolutionizes Analyses of Biological Samples
- Medlab Middle East Looks to The Future of Laboratories
- Medix Biochemica Acquires German Immunoassay Solutions Developer Candor Bioscience
- bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune... Read more
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more